Clinical Trial Search

Primary: Number of Participants With Dose Limiting and Intolerable Treatment-Related Adverse Events (AEs) — 0; 0; 0; 0 participants

Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 266.83; 198.22; 481.11; 668.87 nanograms per milliliter (ng/mL)

Primary: Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0…

Primary: Maximum Observed Concentration (Cmax) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg & Tadalafil 40 mg)…

Primary: Number of Participants With Adverse Events — 5; 6; 6; 6 Participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 2; 0; 2 Participants

Primary: Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set — 69.31; 162.09 ng/mL

Primary: Number of Participants With Adverse Events — 10; 2; 1; 6 Participants

Primary: Incidence of Dose Limiting Toxicities (DLT) — 0; 0; 0 Number of Incidence

Primary: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Total Dabigatran (AUC0-tz). — 667; 192 Nanogram*Hour/ millilitre…

Primary: Maximum Observed Plasma Concentration (Cmax) of Digoxin — 1.94; 2.35 Nanogram per milliliter (ng/mL)

Primary: Part B: PASI (Psoriasis Area and Severity Index) Score Mean Percentage of Change Through Day 43 — 19.88; 17.74; 53.57; 86.04 percentage improvement

Primary: Number of Subjects With Immediate Adverse Events — 0; 0 Participants

Primary: Change in Methane Production — 10645; 14635 parts per million*minutes

Primary: Part 1: Number of Participants With Abnormal Findings in Physical Examinations — 2; 1; 0; 1 Participants